Form 4: Precigen Inc. Secures Private Placement Funding Through Convertible Preferred Stock and Warrants

Precigen Inc. has completed a private placement, issuing convertible preferred stock and warrants to existing and new investors.

Summary

• Precigen Inc. entered into a Securities Purchase Agreement on December 27, 2024, for a private placement.
• The company sold 8.00% Series A Convertible Perpetual Preferred Stock and issued warrants to purchase common stock.
• Randal J. Kirk, a director and 10% owner, reported the transaction on December 30, 2024.
• The preferred stock is convertible into common stock at an initial price of approximately $1.125 per share, subject to adjustments.
• The warrants are exercisable for common stock after shareholder approval at an exercise price of $0.75 per share.
• Randal J. Kirk, through the R.J. Kirk Declaration of Trust, acquired 25,000 shares of preferred stock and 16,666,667 warrants.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company through a successful private placement, but there are potential risks associated with dilution and future cash obligations. The sentiment is moderately positive.

Positives

• The private placement provides Precigen with additional funding.
• The conversion feature of the preferred stock could lead to future equity financing.
• The warrants provide an opportunity for investors to participate in potential future growth.
• The transaction demonstrates continued investment in the company by existing and new investors.

Negatives

• The conversion of preferred stock could dilute existing shareholders.
• The redemption feature of the preferred stock could create a future cash obligation for the company.
• The warrants are exercisable after shareholder approval, which introduces a potential delay.

Risks

• The conversion price of the preferred stock is subject to upward adjustment based on the valuation of the common stock.
• The company needs shareholder approval for the conversion of preferred stock and the exercise of warrants.
• The redemption of preferred stock could impact the company's cash flow.

Future Outlook

The company will need to obtain shareholder approval for the conversion of the preferred stock and the exercise of the warrants. The preferred stock is redeemable for cash at the issuer's option.

Industry Context

Private placements are a common method for companies to raise capital, particularly for those in the biotechnology sector like Precigen. The use of convertible preferred stock and warrants is a typical structure to attract investors.

Comparison to Industry Standards

• The use of convertible preferred stock and warrants is a common practice in the biotech industry for raising capital, similar to companies like XOMA Corporation and Agenus Inc.
• The conversion price of 150% of the warrant exercise price is within the typical range for such transactions.
• The 8% dividend on the preferred stock is a standard rate for this type of financing.

Related Party Transactions

• Randal J. Kirk, a director and 10% owner, participated in the private placement through the R.J. Kirk Declaration of Trust.

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the preferred stock.
• Investors in the private placement will benefit from the potential upside of the warrants and the conversion feature of the preferred stock.
• The company will have additional capital to fund its operations.

Next Steps

• Precigen needs to obtain shareholder approval for the conversion of the preferred stock and the exercise of the warrants.
• The company may redeem the preferred stock for cash at its option.

Key Dates

Keywords

private placement, convertible preferred stock, warrants, equity financing, shareholder approval, Randal J. Kirk, Precigen, funding